Board of Directors
Bhooshi De Silva
Bhooshi De Silva joined PPD as senior vice president of corporate development and strategy in 2014. In this role, he serves as a member of PPD’s executive leadership team, leading the corporate development and strategy functions and co-leading the company’s strategy and innovation governance committee. He partners with the senior leadership team on key strategic initiatives and plays an important role in driving PPD’s evolution and growth. Since joining PPD, Bhooshi has led the organization in completing several strategic partnerships and acquisitions and in strengthening and expanding the company’s capabilities in priority focus areas. Bhooshi was instrumental in PPD’s 2016 acquisition of Evidera, a leading provider of evidence-based solutions to demonstrate the real-world effectiveness and value of biopharmaceutical products. Following the acquisition, Bhooshi’s role expanded to include oversight of Evidera, a wholly owned subsidiary of PPD, which now reports to him.
Prior to joining PPD, Bhooshi had spent 15 years in the biopharmaceutical industry where he held several leadership positions. He started his career at Pfizer, where his roles spanned R&D portfolio management, U.S. commercial development, and U.S. customer strategy and negotiations. In 2009, Bhooshi was named vice president of business development evaluation and strategy, leading a team in the evaluation of licensing, acquisitions and corporate strategic initiatives for Pfizer. Prior to joining PPD, he was head of corporate development, corporate strategy and head of International at Optimer Pharmaceuticals.
Bhooshi holds degrees in finance, economics and engineering from Stanford University, London School of Economics and Imperial College of Science & Technology in London, U.K.
Judd Hartman, Chairman
Mr. Hartman is General Counsel of PPD. He joined PPD in 2001 and has served as the company’s General Counsel since then. He came to PPD from Anker Coal Group, Inc., in Morgantown, W.Va., where he served as Vice President of Legal Affairs. In that position he directed the company’s mergers and acquisitions activities, administered its credit facilities and managed its land department with holdings in West Virginia, Virginia, Maryland and Indiana. Prior to joining Anker, he was a partner at Spilman Thomas & Battle, a regional law firm headquartered in Charleston, W.Va. Mr. Hartman earned a B.S. degree in Economics from Washington and Lee University and a law degree from Wake Forest University.
Mr. Speicher is the Treasurer and Head of Investor Relations for PPD. He is responsible for overseeing the company’s capital raising efforts, liquidity management and hedging activity. In addition, he manages the company’s relationships with banks, ratings agencies and institutional investors. Prior to PPD, he served in the same capacity for Acelity, a medical device company based in San Antonio, Texas. Prior to his career in Treasury, he served as a vice president in the leveraged finance practice at Morgan Stanley in New York. At Morgan Stanley, his focus was on raising debt capital for companies primarily in the healthcare and pharmaceutical sectors. Mr. Speicher earned a B.S. degree in Finance from University of Connecticut.
Richard Wagner, Ph.D., President and CEO
Dr. Wagner co-founded X-Chem in 2009, and is the President, CEO, and member of the Board of Directors. He is member of the Board of Directors of Xios, Inc. and Founder and member of the Board of Directors of X-Rx, Inc., spin-out companies of X-Chem focused on oncology and inflammatory disease. In addition, he founded X-BODY, sold to Juno Therapeutics in 2015. Dr. Wagner was President and CEO of SRU Biosystems, Inc. from 2007 to 2012. Prior to joining SRU, he was Executive Vice President of Research at Praecis Pharmaceuticals, Inc., where he was an inventor of the DirectSelect small molecule screening technology that led to the creation of a ten billion compound screening library. Praecis was acquired by GlaxoSmithKline in 2007. Prior to joining Praecis, Dr. Wagner started operations at Phylos, Inc. in July 1997 as Senior Vice President of Research. At Phylos he was an inventor on several technologies, including a class of antibody mimetics being developed by Bristol Myers Squibb, now called Adnectins™. Earlier, Dr. Wagner had been Director of Cell Biology and a member of management team at Gilead Sciences, Inc. Dr. Wagner received his B.S. in Biochemistry from Trinity College and his Ph.D. in Chemistry from Brown University.